MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

EPZ015666

CAS No. : 1616391-65-1

MCE 站：EPZ015666

产品活性：EPZ015666 (GSK3235025) 是有口服活性的 PRMT5抑制剂，IC₅₀ 为 22 nM。

研究领域：Epigenetics

作用靶点：Histone Methyltransferase

In Vitro: Treatment of MCL cell lines with EPZ015666 (GSK3235025) leads to inhibition of SmD3 methylation and cell death, with IC₅₀ values in the nanomolar range. EPZ015666 (GSK3235025), a potent peptide-competitive and SAM-cooperative inhibitor with >10,000-fold specificity against PRMT5 relative to other methyltransferases.

In Vivo: EPZ015666 (GSK3235025) is orally bioavailable and amenable to in vivo studies. We performed 21-d efficacy studies in severe combined immunodeficiency (SCID) mice bearing subcutaneous Z-138 and Maver-1 xenografts, with twice-daily (BID) oral dosing on four dose groups: 25, 50, 100 and 200 mg per kilogram of body weight (mg/kg). After 21 d of continuous dosing, animals are euthanized, and blood and tissues are analyzed to determine the relationship between methyl-mark pharmacodynamics and tumor-growth inhibition (TGI). EPZ015666 (GSK3235025) showed dose-dependent exposure and TGI after 21 d in both MCL models. Tumors in all EPZ015666 (GSK3235025) dose groups measured on day 21 showed statistically significant differences in weight, volume and tumor growth compared to vehicle-treated tumors. Dosing at 200 mg/kg BID induced tumor stasis in Z-138 cells, with >93% TGI after 21 d, whereas Maver-1 cells showed >70% TGI. Additionally, a third MCL xenograft is tested using the Granta-519 cell line, a fast-growing model that reached endpoint on day 18 and showed dose-dependent efficacy with 45% TGI in the 200 mg/kg group. EPZ015666 (GSK3235025) is well tolerated in all three models, with minimal bodyweight loss in the 200 mg/kg dose group and no other clinical observations.

相关产品：Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Reprogramming Compound Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  3-Deazaneplanocin A hydrochloride  |  Chaetocin  |  UNC0642  |  UNC1999  |  MS023  |  BIX-01294  |  EPZ020411 hydrochloride  |  MM-102 TFA  |  SGC0946  |  A-366  |  Amodiaquine dihydrochloride dihydrate  |  CM-272  |  AZ505  |  SGC707  |  PFI-2 hydrochloride  |  NSC 663284  |  UNC0379  |  A-196  |  Sinefungin  |  SGC3027  |  AMI-1  |  EI1  |  BVT948  |  MS049  |  HLCL-61 hydrochloride  |  UNC0646  |  UNC 0631  |  UNC3866

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。